Need of fostering academic research for bridging the gap of “science- commerce disconnect” in ‘non-profitable’ therapy areas

Authors

  • Anant D. Patil Founder, Plasma Medical Services, Nerul, Navi Mumbai, Maharashtra, India
  • Tushar Balchand Chudiwal Department of Pharmacology, Ananta Institute of Medical Science and Research Center, Rajsamand, Rajasthan
  • Pratishtha Banga Medial Advisor, Sanofi India Ltd

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20164082

Keywords:

Academic research, Financial profit, Patient centricity, Science-commercial disconnect

Abstract

Pharmaceutical companies share the goal of patient benefit with healthcare professionals. However, they are commercial organizations and hence, sometimes, commercial interest may take over science, resulting in “science-commercial disconnect”. This can result in innovation-deficit and financial burden on the patients. Finding new indications for existing drugs and promoting academic research in ‘non-profitable areas’ are some measures to curtail pharmaceutical innovation-deficit. Greater involvement of academicians and non-government organizations in clinical research with government support/funding will help in providing best treatment options to the patients for better outcomes. 

References

Conly JM, Johnston BL. Where are all the new antibiotics? The new antibiotic paradox. Can J Infect Dis Med Microbiol. 2005;16:159-60.

Projan S Why is big pharma getting out of antibacterial drug discovery? Current Opinion in Microbiology. 2003;6:427-30.

Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, damson PC, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54:141-55.

http://www.gene.com/download/pdf/avastin_prescribing.pdf accessed on 23rd January 2016.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf accessed on 23rd January 2016.

Velpandian T, Sharma C, Garg SP, Mandal S, Ghose S. Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. Indian J Ophthalmol. 2007;55:488-90.

http://www.cdsco.nic.in/writereaddata/alert-21-01-2016.pdf accessed on 23rd January 2016.

Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Dowler J, Majjid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.

Ornek K, Karahan ZC, Ergin A, Tekeli A, Tekeli O. Bevacizumab sterility in multiple doses from a single-use vial. Ann Pharmacother. 2008;42:1425-8.

Schreinemachers DM1, Everson RB, Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-46.

Health I. Who needs health care the well or the sick? Bri Medi Jour. 2005;330:954.

Downloads

Published

2016-12-21

How to Cite

Patil, A. D., Chudiwal, T. B., & Banga, P. (2016). Need of fostering academic research for bridging the gap of “science- commerce disconnect” in ‘non-profitable’ therapy areas. International Journal of Basic & Clinical Pharmacology, 5(6), 2295–2297. https://doi.org/10.18203/2319-2003.ijbcp20164082

Issue

Section

Review Articles